Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multifactorial Determinants of Refractory Breathlessness in COPD: Development of the Refractory Breathlessness Score for Risk Stratification.

International journal of chronic obstructive pulmonary disease·2026
Same author

Impact of race-neutral GLI reference equations in Northeast Asian patients with IPF.

BMJ open respiratory research·2026
Same author

Recurrent intracranial hemorrhage without brain metastasis after VEGFR TKI rechallenge in metastatic renal cell carcinoma: a case report and literature review.

Frontiers in oncology·2026
Same author

Efficacy and Safety Profile of a Triple Single-Pill Combination of Valsartan/Amlodipine/Chlorthalidone in Patients with Uncontrolled Hypertension.

Clinical therapeutics·2026
Same author

Predicting climate-driven habitat shifts of Varroa destructor using MaxEnt and CMIP6 data.

Scientific reports·2026
Same author

Impact of Atrial Fibrillation Pattern on Edoxaban Antithrombotic Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease: A Secondary Analysis of the EPIC-CAD Randomized Clinical Trial.

Journal of the American Heart Association·2026

Related Experiment Video

Updated: Jul 6, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

Solid-organ malignancy as a risk factor for tuberculosis.

Hye-Ryoun Kim1, Seung Sik Hwang, Yun Kwan Ro

  • 1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine, Jongno-gu, Seoul 110-744, Korea.

Respirology (Carlton, Vic.)
|April 11, 2008
PubMed
Summary

Solid-organ malignancy significantly increases tuberculosis (TB) risk, particularly when combined with chemotherapy or a history of healed TB. This highlights the need for targeted TB screening in cancer patients.

Related Experiment Videos

Last Updated: Jul 6, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

Area of Science:

  • Oncology
  • Infectious Diseases
  • Epidemiology

Background:

  • Tuberculosis (TB) control requires identifying high-risk individuals.
  • Haematological malignancy is a known risk factor for TB due to immune suppression.
  • The role of solid-organ malignancy in TB development requires further assessment.

Purpose of the Study:

  • To determine if solid-organ malignancy is a risk factor for developing TB.
  • To identify specific risk factors for TB development in cancer patients.

Main Methods:

  • Retrospective cohort study comparing TB incidence in cancer patients and controls.
  • Recruitment of 1809 cancer patients and 1809 controls.
  • 3-year follow-up period to assess TB development.

Main Results:

  • The incidence of active TB was significantly higher in cancer patients (3.07 per 1000 person-years) compared to controls (0.77 per 1000 person-years).
  • Cancer patients had a 4.69 times increased risk of developing TB.
  • Key risk factors identified included chronic renal failure, old healed TB, and anticancer chemotherapy.

Conclusions:

  • Solid-organ malignancy and its treatments (chemotherapy) increase susceptibility to TB reactivation.
  • Cancer patients with a history of old healed TB are especially vulnerable.
  • Immune suppression from cancer and treatment necessitates proactive TB management strategies.